Sanara MedTech stock faces a merger vote after Q2 loss

Sanara MedTech stock faces a decisive corporate checkpoint after the company reported Q2 2026 revenue of USD 28.14 million and adjusted EPS of USD -0.05. The proposed MiMedx merger is scheduled for a shareholder vote on September 30, 2026, making deal approval the key near-term event for SMTI holders.

Q2 revenue misses consensus

According to MarketBeat, Sanara's Q2 revenue of USD 28.14 million fell short of the USD 28.95 million consensus estimate by USD 0.81 million. Adjusted EPS was USD -0.05, compared with the USD -0.02 estimate, a USD 0.03 per-share miss.

The quarterly figures cover the period ended June 30, 2026. Finance results show Q1 revenue of USD 27.80 million and diluted EPS of USD 0.05, so Q2 revenue increased by USD 0.34 million sequentially while earnings moved into a loss.

Merger vote sets the next checkpoint

The definitive proxy statement says Sanara shareholders would receive USD 33.00 in cash plus 0.4735 MiMedx shares for each Sanara share if the transaction closes. StockTitan reports that the special meeting is scheduled for September 30, 2026 at 9:00 a.m. Central Time.

The proposal would end Sanara's separate Nasdaq listing if approved. The proxy statement also says former Sanara shareholders are expected to own 2.9 percent of the combined company, while former MiMedx shareholders would own 97.1 percent, based on September 1, 2026 share counts.

Market value and range

Market data dated September 28, 2026 put Sanara's market capitalization at USD 322.6 million and its 52-week range at USD 16.05 to USD 35.34. Those figures frame the merger consideration against a stock that has been valued near the upper end of its annual range, while the Q2 earnings miss adds a separate operating test to the transaction story.